Nabriva Therapeutics Plc, a Dublin-based biopharmaceutical company, is making waves in the development and commercialization of groundbreaking anti-infective agents aimed at treating serious infections. With a product line that includes SIVEXTRO, an oxazolidinone-class antibacterial drug and XENLETA, a semi-synthetic pleuromutilin antibiotic, the firm is on the front lines in the battle against acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). The company also continues to advance XENLETA, which is currently in Phase I clinical trials and shows promise for the treatment of pediatric infections, sexually transmitted infections, and other conditions. Nabriva’s innovative pipeline also includes the development of CONTEPO, an epoxide antibiotic, which is primed for use in treating complicated urinary tract infections and peri-operative prophylaxis. Incorporated in 2005, Nabriva Therapeutics Plc (formerly known as Nabriva Therapeutics Forschungs GmbH) is a company on the move, poised for groundbreaking discoveries in the world of biopharmaceuticals.
Nabriva Therapeutics plc's ticker is NBRV
The company's shares trade on the NASDAQ stock exchange
They are based in Dublin, Ireland
There are 51-200 employees working at Nabriva Therapeutics plc
It is https://www.nabriva.com/
Nabriva Therapeutics plc is in the Healthcare sector
Nabriva Therapeutics plc is in the Biotechnology industry
The following five companies are Nabriva Therapeutics plc's industry peers: